Findings underscore critical role of product development partnerships in delivering both innovation and access GENEVA (April 24, 2026)—A new peer-reviewed
Country-led evidence and implementation support enabled faster adoption of shorter, more effective regimens worldwide SEOUL (April 13, 2026)—A new independent
Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark
Thuto Pulane, a TB survivor and participant in the NC-009 trial, at a follow-up appointment with Dr. William Brumskine, NC-009
TB Alliance is gratified to see clear progress against tuberculosis in the latest WHO Global TB Control Report. While TB
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing the trajectory of DR-TB care
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms that six-month, all-oral BPaL/M regimens
